NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Adaptive Biotechnologies

Adaptive Biotechnologies

Public
Seattle, WashingtonBiotechhttps://www.adaptivebiotech.com/

Adaptive Biotechnologies is now publicly traded

The data on this page reflects Adaptive Biotechnologies's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Jun 26, 2019

Last Round

Debt

Sep 12, 2022

Total Funding Raised

$1.21B

Company Overview

Adaptive Biotechnologies is a biotechnology company that develops an immune medicine platform for the diagnosis and treatment of various diseases, including cancer and autoimmune conditions.

Sector

Biotech

AI Layer

Application

Keywords

minimal residual diseaseMRDclonoSEQimmune repertoire sequencingcancer diagnosticsimmunomicsT-cell receptorimmune medicinebiomarker discoveryliquid biopsyDNA sequencingdrug discoveryclinical diagnosticsprecision oncologyAI-driven biotech

Adaptive Biotechnologies Comparables

Compare Adaptive Biotechnologies with similar companies based on industry and business-model similarity.

Adaptive Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Adaptive Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtSep 12, 2022
Follow-on OfferingJul 15, 2020
IPOJun 26, 2019
Series F ExtensionDec 11, 2017
Series FMay 6, 2015
Series E
Jan 7, 2015

Key People

Founding team and executive leadership

Harlan Robins

co-founder and chief Scientific Officer

Founding Team

Chad Robins

CEO & Co-Founder

Founding Team

Julie Rubinstein

President and Chief Operating Officer

Executive Team

Kyle Piskel

Chief Financial Officer

Executive Team

Adaptive Biotechnologies Investors

Notable investors and investment history

Adaptive Biotechnologies investors
InvestorRounds
Guggenheim SecuritiesIPO, Follow-on Offering
BofA SecuritiesFollow-on Offering
OrbiMedDebt
BD BiosciencesSeries F
Walden Venture CapitalSeries A
Viking Global InvestorsSeries F, Series F Extension, Series C
Senator Investment GroupSeries F

Adaptive Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Adaptive Biotechnologies Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range652
Year Founded2009
Last FundingSep 12, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.